
CTI BioPharma Corp. CTIC
Quarterly report 2023-Q1
added 05-15-2023
CTI BioPharma Corp. Cost of Revenue 2011-2026 | CTIC
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue CTI BioPharma Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.51 M | - | - | - | 879 K | 364 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.51 M | 364 K | 1.59 M |
Quarterly Cost of Revenue CTI BioPharma Corp.
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.22 M | - | 1.15 M | 917 K | 278 K | - | - | - | - | - | - | - | - | - | - | - | - | - | 114 K | 588 K | - | - | 69 K | 78 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.22 M | 69 K | 552 K |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
32.2 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
40 K | - | -10.17 % | $ 12.2 K | ||
|
Biogen
BIIB
|
2.31 B | $ 177.93 | -4.15 % | $ 25.9 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
17.3 M | $ 65.89 | -0.06 % | $ 8.81 B | ||
|
Midatech Pharma plc
MTP
|
926 K | - | -18.52 % | $ 27.3 M | ||
|
AstraZeneca PLC
AZN
|
12.4 B | $ 94.4 | 0.82 % | $ 96.9 B | ||
|
BeiGene, Ltd.
BGNE
|
70.7 M | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
436 K | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
24.8 M | - | -7.31 % | $ 87 M | ||
|
Ascendis Pharma A/S
ASND
|
3.52 M | $ 214.55 | 2.77 % | $ 5 B | ||
|
Bristol-Myers Squibb Company
BMY
|
14 B | $ 55.84 | 0.13 % | $ 113 B | ||
|
Acasti Pharma
ACST
|
76 K | - | 4.01 % | $ 150 M | ||
|
Caladrius Biosciences
CLBS
|
31.1 M | - | -16.75 % | $ 25.8 M | ||
|
Clearside Biomedical
CLSD
|
355 K | - | - | $ 25.3 M | ||
|
Chimerix
CMRX
|
447 K | - | - | $ 756 M | ||
|
BioNTech SE
BNTX
|
2.91 B | $ 106.88 | 4.6 % | $ 27.2 B | ||
|
AIkido Pharma
AIKI
|
9 K | - | 1.93 % | $ 17.4 M | ||
|
Catalyst Biosciences
CBIO
|
4.64 M | $ 11.09 | 1.0 % | $ 730 M | ||
|
Albireo Pharma
ALBO
|
1.36 M | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
238 M | - | - | $ 867 M | ||
|
Ayala Pharmaceuticals
AYLA
|
602 K | - | - | $ 7.46 M | ||
|
Coherus BioSciences
CHRS
|
159 M | $ 1.69 | 2.12 % | $ 159 M | ||
|
Ampio Pharmaceuticals
AMPE
|
369 K | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
358 M | $ 28.99 | -1.39 % | $ 1.4 B | ||
|
Celldex Therapeutics
CLDX
|
200 K | $ 25.71 | 0.16 % | $ 1.66 M | ||
|
Cellectis S.A.
CLLS
|
31.4 M | $ 4.24 | -0.47 % | $ 116 M | ||
|
Acorda Therapeutics
ACOR
|
15.3 M | - | -24.86 % | $ 820 K |